Status:
COMPLETED
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
Yale University
Conditions:
Behavior Therapy
Cocaine
Eligibility:
All Genders
21-55 years
Phase:
PHASE2
Brief Summary
Although LAAM, a derivative of methadone, has been successfully used as an alternative to methadone maintenance in opioid addicts, its effect on concurrent opioid and cocaine abuse has not been ascert...
Detailed Description
One hundred forty male and female opioid-dependent cocaine abusers will be stratified by sex and randomly assigned to one of four treatment groups according to a 2 x 2 experimental design: low-dose LA...
Eligibility Criteria
Inclusion
- One hundred forty male and female cocaine-abusing, opioid-dependent individuals between the ages 21-55, with at least 40% women and 40% Afro-Americans, who not be currently enrolled in treatment, will be entered into the study. Subjects must have current opioid dependence as evidenced by documentation of prior treatment for opioid dependence or signs of withdrawal upon administration of naloxone (0.8 mg, i.m.), and opioid-positive urine screen. Subjects also must be current users of cocaine with self-reported use of \> 12 gms during the preceding 12 months, self-reported use of \> 1 gm/week in the month preceding study entry, and cocaine-positive urine screen. Subjects must fulfill DSM-III-R criteria for opioid and cocaine dependence. These criteria will be ascertained using the substance abuse section of the SCID interview developed for use with DSM-III-R
Exclusion
- Criteria for exclusion include current diagnosis of other drug or alcohol dependence (other than opiates, cocaine or tobacco); ill health (e.g., major cardiovascular, renal, endocrine, hepatic disorder); respiratory condition (e.g., asthma); history of major psychiatric disorder (psychosis, schizophrenia, bipolar, major depression); current suicidality; LFT's (i.e., liver enzymes) greater than 3 times normal levels; and pregnancy.
Key Trial Info
Start Date :
March 1 1997
Trial Type :
INTERVENTIONAL
End Date :
August 1 2001
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00158288
Start Date
March 1 1997
End Date
August 1 2001
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516